{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:40:32Z","timestamp":1777977632893,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In 2006, Senegal adopted artemisinin-based combination therapy (ACT) as first-line treatment in the management of uncomplicated malaria. This study aimed to update the status of antimalarial efficacy more than ten years after their first introduction. This was a randomized, three-arm, open-label study to evaluate the efficacy and safety of artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) in Senegal. Malaria suspected patients were screened, enrolled, treated, and followed for 28 days for AL and ASAQ arms or 42 days for DP arm. Clinical and parasitological responses were assessed following antimalarial treatment. Genotyping (<jats:italic>msp1<\/jats:italic>, <jats:italic>msp2<\/jats:italic> and 24 SNP-based barcode) were done to differentiate recrudescence from re-infection; in case of PCR-confirmed treatment failure, <jats:italic>Pfk13<\/jats:italic> propeller and <jats:italic>Pfcoronin<\/jats:italic> genes were sequenced. Data was entered and analyzed using the WHO Excel-based application. A total of 496 patients were enrolled. In Diourbel, PCR non-corrected\/corrected adequate clinical and parasitological responses (ACPR) was 100.0% in both the AL and ASAQ arms. In Kedougou, PCR corrected ACPR values were 98.8%, 100% and 97.6% in AL, ASAQ and DP arms respectively. No <jats:italic>Pfk13<\/jats:italic> or <jats:italic>Pfcoronin<\/jats:italic> mutations associated with artemisinin resistance were found. This study showed that AL, ASAQ and DP remain efficacious and well-tolerated in the treatment of uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria in Senegal.<\/jats:p>","DOI":"10.1038\/s41598-020-65553-5","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T10:03:14Z","timestamp":1591005794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal"],"prefix":"10.1038","volume":"10","author":[{"given":"Mamadou Alpha","family":"Diallo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamadou Samb","family":"Yade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaye Die","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahima","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khadim","family":"Diongue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saidou Abdoul","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouhamad","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mame Cheikh","family":"Seck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouhamadou","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baba","family":"Dieye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules Fran\u00e7ois","family":"Gomis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djiby","family":"Sow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awa Bineta","family":"D\u00e8me","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida Sadikh","family":"Badiane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daouda","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"65553_CR1","doi-asserted-by":"crossref","unstructured":"Trape, J. et al. The rise and fall of malaria in a west African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study. Lancet Infect. Dis. 14, 476\u2013488 (2014).","DOI":"10.1016\/S1473-3099(14)70712-1"},{"key":"65553_CR2","doi-asserted-by":"publisher","unstructured":"Sinclair, D., Zani, B., Donegan, S., Olliaro, P. & Garner, P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD007483.pub2 (2009).","DOI":"10.1002\/14651858.CD007483.pub2"},{"key":"65553_CR3","unstructured":"USAID. Evaluation of the Impact of the Scale-up of Malaria Control Interventions on All- Cause Mortality in Children under Five Years of Age in Senegal. USAID (2015)."},{"key":"65553_CR4","unstructured":"Kone, G. K., Audibert, M., Lalou, R., Lafarge, H. & Le Hersan, J.-Y. Subsidized antimalarial drugs in Dakar (Senegal): Do the poor benefit? Etudes Doc. 1\u201325 (2017)."},{"key":"65553_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-334","volume":"11","author":"S Thiam","year":"2012","unstructured":"Thiam, S. et al. Scale-up of home-based management of malaria based on rapid diagnostic tests and artemisinin-based combination therapy in a resource-poor country: results in Senegal. Malar. J. 11, 334 (2012).","journal-title":"Malar. J."},{"key":"65553_CR6","first-page":"1","volume":"14","author":"C Naing","year":"2019","unstructured":"Naing, C., Whittaker, M. A., Htet, N. H., Aye, S. N. & Mak, J. W. Efficacy of antimalarial drugs for treatment of uncomplicated falciparum malaria in Asian region: A network meta-analysis. Plos one 14, 1\u201316 (2019).","journal-title":"Plos one"},{"key":"65553_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley, E. A. et al. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. N. Engl. J. Med. 371, 411\u2013423 (2014).","journal-title":"N. Engl. J. Med."},{"key":"65553_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1172\/JCI21682","volume":"113","author":"NJ White","year":"2004","unstructured":"White, N. J. Antimalarial drug resistance. J. Clin. Invest. 113, 1084\u20131092 (2004).","journal-title":"J. Clin. Invest."},{"key":"65553_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-12-1","volume":"12","author":"D Van Tyne","year":"2013","unstructured":"Van Tyne, D. et al. Changes in drug sensitivity and anti-malarial drug resistance mutations over time among Plasmodium falciparum parasites in Senegal. Malar. J. 12, 1\u201310 (2013).","journal-title":"Malar. J."},{"key":"65553_CR10","unstructured":"WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. (World Health Organization, 2018)."},{"key":"65553_CR11","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. World Health Organization doi:ISBN 978 92 4 159753 1 (2009)."},{"key":"65553_CR12","unstructured":"Basco, L. K. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. World Heal. Organ. 191 (2007)."},{"key":"65553_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50\u201355 (2014).","journal-title":"Nature"},{"key":"65553_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-016-1095-y","volume":"15","author":"J Muwanguzi","year":"2016","unstructured":"Muwanguzi, J. et al. Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malar. J. 15, 36 (2016).","journal-title":"Malar. J."},{"key":"65553_CR15","doi-asserted-by":"publisher","first-page":"12799","DOI":"10.1073\/pnas.1812317115","volume":"115","author":"AR Demas","year":"2018","unstructured":"Demas, A. R. et al. Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility. Proc. Natl. Acad. Sci. 115, 12799\u201312804 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"65553_CR16","unstructured":"World Health Organization. Status report on artemisinin resistance and ACT efficacy. World Health Organization (2018)."},{"key":"65553_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.4269\/ajtmh.16-0053","volume":"95","author":"B Dieye","year":"2016","unstructured":"Dieye, B. et al. West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia. Am. J. Trop. Med. Hyg. 95, 1054\u20131060 (2016).","journal-title":"J. Trop. Med. Hyg."},{"key":"65553_CR18","first-page":"608","volume":"15","author":"B Faye","year":"2010","unstructured":"Faye, B. et al. Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: Multisite trial in Senegal and Ivory Coast. Trop. Med. Int. Heal. 15, 608\u2013613 (2010).","journal-title":"Trop. Med. Int. Heal."},{"key":"65553_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-198","volume":"10","author":"W Yavo","year":"2011","unstructured":"Yavo, W. et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar. J. 10, 198 (2011).","journal-title":"Malar. J."},{"key":"65553_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-185","volume":"10","author":"H Menan","year":"2011","unstructured":"Menan, H. et al. Comparative study of the efficacy and tolerability of dihydroartemisinin - Piperaquine - trimethoprim versus artemether - Lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. Malar. J. 10, 185 (2011).","journal-title":"Malar. J."},{"key":"65553_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.trstmh.2008.05.016","volume":"102","author":"A Souares","year":"2008","unstructured":"Souares, A., Lalou, R., Sene, I., Sow, D. & Le Hesran, J. Y. Adherence and effectiveness of drug combination in curative treatment among children suffering uncomplicated malaria in rural Senegal. Trans. R. Soc. Trop. Med. Hyg. 102, 751\u2013758 (2008).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"65553_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-416","volume":"11","author":"RC Tine","year":"2012","unstructured":"Tine, R. C. et al. Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: Open randomized trial. Malar. J. 11, 1 (2012).","journal-title":"Malar. J."},{"key":"65553_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4269\/ajtmh.2010.09-0265","volume":"82","author":"B Faye","year":"2010","unstructured":"Faye, B. et al. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am. J. Trop. Med. Hyg. 82, 140\u2013144 (2010).","journal-title":"J. Trop. Med. Hyg."},{"key":"65553_CR24","first-page":"45","volume":"26","author":"D Sow","year":"2019","unstructured":"Sow, D. et al. Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine. Med. Sante Trop. 26, 45\u201350 (2019).","journal-title":"Med. Sante Trop."},{"key":"65553_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-6-80","volume":"6","author":"B Faye","year":"2007","unstructured":"Faye, B. et al. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar. J. 6, 1\u20139 (2007).","journal-title":"Malar. J."},{"key":"65553_CR26","doi-asserted-by":"crossref","unstructured":"Sylla, K. et al. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: Results from two years surveillance. BMC Infect. Dis. 13, (2013).","DOI":"10.1186\/1471-2334-13-598"},{"key":"65553_CR27","unstructured":"Programme National de Lutte contre le Paludisme (PNLP). Plan strat\u00e9gique national de lutte contre le paludisme 2016\u20132020 (2015)."},{"key":"65553_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-018-2524-x","volume":"17","author":"MA Kakolwa","year":"2018","unstructured":"Kakolwa, M. A. et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar. J. 17, 1\u201310 (2018).","journal-title":"Malar. J."},{"key":"65553_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-13-309","volume":"13","author":"A Nhama","year":"2014","unstructured":"Nhama, A. et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: A multisite, open-label, two-cohort, clinical trial in Mozambique. Malar. J. 13, 1\u20139 (2014).","journal-title":"Malar. J."},{"key":"65553_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-019-2864-1","volume":"18","author":"M Warsame","year":"2019","unstructured":"Warsame, M. et al. High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malar. J. 18, 1\u201311 (2019).","journal-title":"Malar. J."},{"key":"65553_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-015-0775-3","volume":"14","author":"G Getnet","year":"2015","unstructured":"Getnet, G. et al. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia. Malar. J. 14, 1\u20137 (2015).","journal-title":"Malar. J."},{"key":"65553_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0154618","volume":"11","author":"D Nega","year":"2016","unstructured":"Nega, D. et al. Therapeutic efficacy of artemether-lumefantrine (Coartem) in treating uncomplicated P. falciparum malaria in Metehara, Eastern Ethiopia: Regulatory clinical study. Plos one 11, 1\u201314 (2016).","journal-title":"Plos one"},{"key":"65553_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0176004","volume":"12","author":"M Teklemariam","year":"2017","unstructured":"Teklemariam, M., Assefa, A., Kassa, M., Mohammed, H. & Mamo, H. Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. Plos one 12, 1\u201318 (2017).","journal-title":"Plos one"},{"key":"65553_CR34","doi-asserted-by":"publisher","first-page":"634","DOI":"10.4269\/ajtmh.15-0503","volume":"94","author":"K Niar\u00e9","year":"2016","unstructured":"Niar\u00e9, K. et al. In vivo efficacy and parasite clearance of artesunate + sulfadoxine-pyrimethamine versus artemether-lumefantrine in Mali. Am. J. Trop. Med. Hyg. 94, 634\u2013639 (2016).","journal-title":"J. Trop. Med. Hyg."},{"key":"65553_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-016-1381-8","volume":"15","author":"AM Dorkenoo","year":"2016","unstructured":"Dorkenoo, A. M. et al. Therapeutic efficacy trial of artemisinin-based combination therapy for the treatment of uncomplicated malaria and investigation of mutations in k13 propeller domain in Togo, 2012\u20132013. Malar. J. 15, 1\u20139 (2016).","journal-title":"Malar. J."},{"key":"65553_CR36","doi-asserted-by":"publisher","first-page":"e02116","DOI":"10.1128\/AAC.02116-16","volume":"61","author":"E Talundzic","year":"2017","unstructured":"Talundzic, E. et al. Molecular Epidemiology of Plasmodium falciparum kelch13 Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing. Antimicrob. Agents Chemother. 61, e02116\u201316 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"65553_CR37","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1907142116","volume":"116","author":"TP Velavan","year":"2019","unstructured":"Velavan, T. P., Nderu, D., Agbenyega, T., Ntoumi, F. & Kremsner, P. G. An alternative dogma on reduced artemisinin susceptibility: A new shadow from east to west. Proc. Natl. Acad. Sci. 116, 12611\u201312612 (2019).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"65553_CR38","doi-asserted-by":"publisher","first-page":"12613","DOI":"10.1073\/pnas.1907920116","volume":"116","author":"AI Sharma","year":"2019","unstructured":"Sharma, A. I., Demas, A. R., Hartl, D. L. & Wirth, D. F. Polymorphisms of pfcoronin in natural populations: Implications for functional significance. Proc. Natl. Acad. Sci. USA 116, 12613\u201312614 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65553_CR39","doi-asserted-by":"publisher","first-page":"12556","DOI":"10.1073\/pnas.1818287115","volume":"115","author":"RC Henrici","year":"2018","unstructured":"Henrici, R. C. & Sutherland, C. J. Alternative pathway to reduced artemisinin susceptibility in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 115, 12556\u201312558 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65553_CR40","unstructured":"Programme National de Lutte contre le Paludisme (PNLP). Bulletin \u00e9pid\u00e9miologique annuel du paludisme au S\u00e9n\u00e9gal. (2018)."},{"key":"65553_CR41","unstructured":"WHO. Management of severe malaria. (World Health Organization, 2012)."},{"key":"65553_CR42","unstructured":"WHO. Malaria microscopy quality assurance manual. (WHO, 2015)."},{"key":"65553_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-7-223","volume":"7","author":"R Daniels","year":"2008","unstructured":"Daniels, R. et al. A general SNP-based molecular barcode for Plasmodium falciparum identification and tracking. Malar. J. 7, 223 (2008).","journal-title":"Malar. J."},{"key":"65553_CR44","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.1073\/pnas.1505691112","volume":"112","author":"RF Daniels","year":"2015","unstructured":"Daniels, R. F. et al. Modeling malaria genomics reveals transmission decline and rebound in Senegal. Proc. Natl. Acad. Sci. USA 112, 7067\u20137072 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65553_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2695-0","volume":"18","author":"J Fulakeza","year":"2019","unstructured":"Fulakeza, J. et al. Comparison of msp genotyping and a 24 SNP molecular assay for differentiating Plasmodium falciparum recrudescence from reinfection. Malar. J. 18, 84 (2019).","journal-title":"Malar. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65553-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65553-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65553-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:32:03Z","timestamp":1670326323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65553-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65553"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65553-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8907"}}